Biocon: Slow Humira Biosimilar Uptake But Payer Landscape Evolving
Biocon bets on dual pricing strategy in the US amid a “more gradual” than expected uptake of biosimilar adalimumab but emphasizes that payer positions aren’t “definitive” yet.
Biocon bets on dual pricing strategy in the US amid a “more gradual” than expected uptake of biosimilar adalimumab but emphasizes that payer positions aren’t “definitive” yet.